Intellia Therapeutics (NASDAQ:NTLA) CAO Sells $23,169.52 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael Dube sold 1,864 shares of Intellia Therapeutics stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $12.43, for a total value of $23,169.52. Following the transaction, the chief accounting officer directly owned 65,022 shares of the company’s stock, valued at $808,223.46. The trade was a 2.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $12.60 on Friday. The company has a market capitalization of $1.77 billion, a PE ratio of -3.75 and a beta of 1.80. Intellia Therapeutics, Inc. has a 52-week low of $7.95 and a 52-week high of $28.25. The business’s fifty day moving average is $12.18 and its 200 day moving average is $13.21.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The business had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. During the same period in the previous year, the business earned ($0.98) earnings per share. The firm’s revenue was down 46.4% on a year-over-year basis. On average, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -3.21 EPS for the current fiscal year.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Farther Finance Advisors LLC grew its holdings in shares of Intellia Therapeutics by 289.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,144 shares of the company’s stock valued at $26,000 after purchasing an additional 1,594 shares during the last quarter. Freestone Grove Partners LP bought a new position in shares of Intellia Therapeutics during the second quarter valued at about $33,000. Nykredit A S bought a new position in shares of Intellia Therapeutics during the second quarter valued at about $33,000. Integrated Wealth Concepts LLC purchased a new position in shares of Intellia Therapeutics in the second quarter worth about $34,000. Finally, Fifth Third Bancorp purchased a new position in shares of Intellia Therapeutics in the first quarter worth about $38,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

NTLA has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Friday, July 17th. New Street Research set a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price target for the company. in a research note on Wednesday, July 15th. Canaccord Genuity Group reissued a “buy” rating and issued a $49.00 price target on shares of Intellia Therapeutics in a report on Tuesday, June 16th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have assigned a Hold rating and five have assigned a Sell rating to the company’s stock. According to MarketBeat, Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $20.72.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient’s body.

Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema.